Dry AMD and GA: The Present and Future

What Is AMD?

Clinical Features of AMD

Characteristics of Early AMD

Characteristics of Intermediate AMD

Characteristics of Advanced AMD

Pathophysiology of AMD

Dry AMD and Atrophy Associated With Increased Lipofuscin/A2E

Amyloid Found in Dry AMD

Complement Activation in Dry AMD

Genetic Correlations Between Complement Cascade and AMD

Risk Factors for AMD

Symptoms of AMD

Diagnosis of AMD

Benefit of Supplementation in AMD AREDS Study

Evaluation of Further Supplementation AREDS2 Study

Current Management in Early AMD

Current Management of Intermediate AMD

Current Management of Advanced AMD

Summary: Dry AMD Treatment in 2016

Emerging Therapeutic Strategies in Dry AMD

Visual Cycle Modulation

Emixustat: Potential Mechanism of Action

Phase 2b/3 Trial of Emixustat SEATTLE Study

Anti-Amyloid Antibodies

Neuroprotection

Global Inflammation Suppression

Complement Inhibition C5 and C3 Inhibitors

Lampalizumab (Anti-Factor D)

Phase 2 MAHALO Study of Lampalizumab in GA Secondary to AMD

Efficacy Results From MAHALO Study

Lampalizumab Phase 3 Trials CHROMA and SPECTRI

Stem Cell Therapy for Atrophic AMD

hESC RPE Phase 1/2 Study Surgical Approach

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)